Preparation and characterization of intravenously injectable curcumin nanosuspension

Drug Delivery

Volumn 18, Issue 2, 2011, Pages 131-142

  Gao, Yan ^a   Li, Zhonggang ^a   Sun, Min ^a   Guo, Chenyu ^a   Yu, Aihua ^a   Xi, Yanwei ^a   Cui, Jing ^b   Lou, Hongxiang ^a   Zhai, Guangxi ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Curcumin; Cytotoxicity; High pressure homogenization; Nanosuspension; Vascular irritation.

Indexed keywords

CURCUMIN; NANOPARTICLE; NANOSUSPENSION; PHOSPHATIDYLCHOLINE; POLOXAMER; POLYSORBATE 80; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DISSOLUTION; DRUG SAFETY; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; HELA CELL; HEMOLYSIS; HUMAN; HUMAN CELL; NONHUMAN; PARTICLE SIZE; PHLEBITIS; PRIORITY JOURNAL; RABBIT; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; CURCUMIN; DRUG STABILITY; ERYTHROCYTES; FREEZE DRYING; HELA CELLS; HEMOLYSIS; HUMANS; INJECTIONS, INTRAVENOUS; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS; PHYSICOCHEMICAL PROCESSES; RABBITS; SUSPENSIONS;

EID: 78650778104     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2010.520353     Document Type: Article

References (44)

1. Aggarwal, B.B., Harikumar, K.B. (2009). Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol. 41:40-59.
2. Anand, P., Kunnumakkara, A.B., Newman, R.A., Aggarwal, B.B. (2007). Bioavailability of Curcumin: Problems and promises. Mol Pharm. 4:807-18.
3. Baba, K., Pudavar, H.E., Roy, I., Ohulchanskyy, T.Y., Chen, Y., Pandey, R.K., Prasad, P.N. (2006). New method for delivering a hydrophobic drug for photodynamic therapy using pure nanocrystal form of the drug. Mol Pharm. 4:289-97.
4. Bisht, S., Feldmann, G., Soni, S., Ravi, R., Karikar, C., Maitra, A. (2007). Polymeric nanoparticles encapsulated curcumin ("nanocurcumin") : A novel strategy for human cancer therapy. J Nanobiotechnol. 5:3-20.
5. Cadwallader, D.E., Ansel, H.C. (1965). Hemolysis of erythrocytes by antibacterial preservatives II. Quaternary ammonium salts. J Pharm Sci. 54:1010-2.
6. Cheng, A.L., Hsu, C.H., Lin, J.K., Hsu, M.M., Ho, Y.F., Shen, T.S., Ko, J.Y., Lin, J.T., Lin, B.R., Ming-Shiang, W., Yu, H.S., Jee, S.H., Chen, G.S., Chen, T.M., Chen, C.A., Lai, M.K., Pu, Y.S., Pan, M.H., Wang, Y.J., Tsai, C.C., Hsieh, C.Y. (2001). Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 21:2895-900.
7. Cui, J., Yu, B., Zhao, Y., Zhu, W.W., Li, H.L., Lou, H.X., Zhai, G.X. (2009). Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems. Int J Pharm. 371:148-55.
8. Douroumis, D., Fahr, A. (2006). Nano- and micro-particulate formulations of poorly water-soluble drugs by using a novel optimized technique. Eur J Pharm Biopharm. 63:173-5.
9. Egan, M.E., Pearson, M., Weiner, S.A., Rajendran, V., Rubin, D., Glockner-Pagel, J., Canny, S., Du, K., Lukacs, G.L., Caplan, M.J. (2004). Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science. 304:600-2.
10. Ganta, S., Amiji, M. (2009). Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm. 6:928-39.
11. Ganta, S., Paxton, J.W., Baguley, B.C., Garg, S. (2008). Formulation and pharmacokinetics evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int J Pharm. 367:179-86.
12. Hansch, C., Glave, W.R. (1971). Structure-activity relationships in membrane-perturbing agents hemolytic, narcotic, and antibacterial compounds. Mol Pharmacol. 7:337-54.
13. Hatcher, H., Planalp, R., Cho, J., Torti, F.M., Torti, S.V. (2008). Curcumin: From ancient medicine to current clinical trials. Cell Mol Life Sci. 65:1631-52.
14. He, J., Feng, J.F., Zhang, L.L., Lu, W.G., Hou, S.X. (2005). Freeze-drying of silymarin-loaded solid lipid nanoparticles (SM-SLN). Chin J Chin Materia Medica. 30:110-2.
15. Iwunze, M.O. (2004). Binding and distribution characteristics of curcumin solubilized in CTAB micelle. J Mol Liq. 11:161-5.
16. Jacobs, C., Kayser, O., Müller, R.H. (2000). Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int J Pharm. 196:161-4.
17. Keck, C.M., Müller, R.H. (2006). Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur J Pharm Biopharm. 62:3-16.
18. Kesisoglou, F., Panmai, S., Wu, Y. (2007). Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 59:631-44.
19. Kim, C.K., Kim, J.H., Park, K.M., Oh, K.H., Oh, U., Hwang, S.J. (1997). Preparation and evaluation of a titrated extract of centella asiatica injection in the form of an extemporaneous micellar solution. Int J Pharm. 146:63-70.
20. Kosto, T.J., Nauman, E.B. (2003). A density-functional model for controlled release. J Contr Rel. 93:301-8.
21. Kumar, M.P., Rao, Y.M., Apte, S. (2008). Formulation of nanosuspensions of albendazole for oral administration. Curr Nanosci. 4:53-8.
22. Kurd, S.K., Smith, N., Van Voorhees, A., Troxel, A.B., Badmaev, V., Seykora, J.T., Gelfand, J.M. (2008). Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial. J Am Acad Dermatol. 58:625-31.
23. Kuttan, R., Sudheeran, P.C., Josph, C.D. (1987). Turmeric and curcumin as topical agents in cancer therapy. Tumori. 73:29-31.
24. Lao, C.D., Ruffin, M.T., Normolle, D., Heath, D.D., Murray, S.I., Bailey, J.M., Boggs, M.E., Crowell, J., Rock, C.L., Brenner, D.E. (2006). Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 6:1-4.
25. Li, L., Braiteh, F.S., Kurzrock, R. (2005). Liposome-encapsulated curcumin: In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer. 104:1322-31.
26. Lou, H., Zhang, X., Gao, L., Feng, F., Wang, J., Wei, X., Yu, Z., Zhang, D., Zhang, Q. (2009). In vitro and in vivo antitumor activity of oridonin nanosuspension. Int J Pharm. 379:181-6.
27. Lv, Q.Z., Yu, A.H., Xi, Y.W., Li, H.L., Song, Z.M., Cui, J., Cao, F.L., Zhai, G.X. (2009). Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery. Int J Pharm. 372:191-8.
28. Ma, Z.S., Shayeganpour, A., Brocks, D.R., Lavasanifar, A., Samuel, J. (2007). High-performance liquid chromatography analysis of curcumin in rat plasma: Application to pharmacokinetics of polymeric micellar formulation of curcumin. Biomed Chromatogr. 21:546-52.
29. Maiti, K., Mukherjee, K., Gantait, A., Saha, B.P., Mukherjee, P.K. (2007). Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm. 330:155-63.
30. Manjunath, K., Venkateswarlu, V. (2005). Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Contr Rel. 107:215-28.
31. Mauludin, R., Müller, R.H., Keck, C.M. (2009). Kinetic solubility and dissolution velocity of rutin nanocrystals. Eur J Pharm Sci. 36:502-10.
32. McSweeney, S.L., Healy, R., Mulvihill, D.M. (2008). Effect of lecithin and monoglycerides on the heat stability of a model infant formula emulsion. Food Hydrocol. 22:888-98.
33. Müller, R.H., Jacobs, C., Kayser, O. (2001). Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 47:3-19.
34. Paradkar, A., Ambike, A.A., Jadhav, B.K., Mahadik, K.R. (2004), Characterization of curcumin-PVP solid dispersion obtained by spray drying. Int J Pharm. 271:281-6.
35. Rabinow, B., Kipp, J., Papadopoulos, P., Wong, J., Glosson, J., Gass, J., Sun, C.S., Wielgos, T., White, R., Cook, C., Barker, K., Wood, K. (2007). Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int J Pharm. 339:251-60.
36. Rabinow, B.E. (2004). Nanosuspensions in drug delivery. Nat Rev Drug Discov. 3:785-96.
37. Sharma, R.A., Euden, S.A., Platton, S.L., Cooke, D.N., Shafayat, A., Hewitt, H.R., Marczylo, T.H., Morgan, B., Hemingway, D., Plummer, S.M., Pirmohamed, M., Gescher, A.J., Steward, W.P. (2004). Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin Cancer Res. 10:6847-54.
38. Sharma, R.A., Steward, W.P., Gescher, A.J. (2007). Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol. 595:453-70.
39. Singh, M., Singh, N. (2009). Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells. Mol Cell Biochem. 325:107-19.
40. Sou, K., Inenaga, S., Takeoka, S., Tsuchida, E. (2008). Loading of curcumin into macrophages using lipid-based nanoparticles. Int J Pharm. 352:287-93.
41. Tonnesen, H.H., Masson, M., Loftsson, T. (2002). Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: Solubility, chemical and photochemical stability. Int J Pharm. 244:127-35.
42. Trotta, M., Gallarate, M., Pattarino, F., Morel, S. (2001). Emulsions containing partially water-miscible solvents for the preparation of drug nanosuspensions. J Contr Rel. 76:119-28.
43. Voorhees, P.W. (1985). The theory of Ostwald ripening. J Stat Phys. 38:231-52.
44. Xiong, R., Lu, W., Li, J., Wang, P., Xu, R., Chen, T. (2008). Preparation and characterization of intravenously injectable nimodipine nanosuspension. Int J Pharm. 350:338-43.